Details of the Drug Transporter (DTP)

General Information of Drug Transporter (DTP) (ID: DTPATLS)

• DTP Name: Fly-like putative transporter 2 (SLC22A16)
• Gene Name: SLC22A16
• UniProt ID: Q86VW1 (S22AG_HUMAN)
• VARIDT ID: DTD0142
• Synonyms: OCT6; CT2; Carnitine transporter 2; FLIPT2; Flipt 2; HEL-S-18; OKB1; Organic cation transporter OKB1; SLC22A16; Solute carrier family 22 member 16; dJ261K5.1; Organic cation/carnitine transporter 6
• DTP Family:
  Major Facilitator Superfamily (MFS)
  Organic Cation Transporter (OCT) Family
• Tissue Specificity: Widely expressed at low levels in adulttissues and fetal brain, lung, liver and kidney. Expressed intestis and epididymis (at protein level). Expressed at lowerlevels in bone marrow and fetal liver. Expressed in hematopoieticcells, including CD34(+) leukocytes and leukemia cells. Abundantlyexpressed in ovarian cancer clear-cell adenocarcinoma. Expressedin endometrium (at protein level); highly expressed during thenormal secretory phase, but expression is significantly reduced inthe proliferative phase.
• Sequence:
  MGSRHFEGIYDHVGHFGRFQRVLYFICAFQNISCGIHYLASVFMGVTPHHVCRPPGNVSQ
  VVFHNHSNWSLEDTGALLSSGQKDYVTVQLQNGEIWELSRCSRNKRENTSSLGYEYTGSK
  KEFPCVDGYIYDQNTWKSTAVTQWNLVCDRKWLAMLIQPLFMFGVLLGSVTFGYFSDRLG
  RRVVLWATSSSMFLFGIAAAFAVDYYTFMAARFFLAMVASGYLVVGFVYVMEFIGMKSRT
  WASVHLHSFFAVGTLLVALTGYLVRTWWLYQMILSTVTVPFILCCWVLPETPFWLLSEGR
  YEEAQKIVDIMAKWNRASSCKLSELLSLDLQGPVSNSPTEVQKHNLSYLFYNWSITKRTL
  TVWLIWFTGSLGFYSFSLNSVNLGGNEYLNLFLLGVVEIPAYTFVCIAMDKVGRRTVLAY
  SLFCSALACGVVMVIPQKHYILGVVTAMVGKFAIGAAFGLIYLYTAELYPTIVRSLAVGS
  GSMVCRLASILAPFSVDLSSIWIFIPQLFVGTMALLSGVLTLKLPETLGKRLATTWEEAA
  KLESENESKSSKLLLTTNNSGLEKTEAITPRDSGLGE
• Function: This sodium-ion dependent transporter mediates the uptake of carnitine. Also transports organic cations such as tetraethylammonium (TEA) and doxorubicin. Thought to mediate the L-carnitine secretion mechanism from testis epididymal epithelium into the lumen which is involved in the maturation of spermatozoa. The uptake of TEA is inhibited by various organic cations.
• Endogenous Substrate(s): Carnitine
• TCDB ID: 2.A.1.19.12
• Gene ID: 85413
• Reactome Pathway: Organic cation transport (R-HSA-549127)

Molecular Interaction Atlas (MIA) of This DTP

2 Approved Drug(s) Transported by This DTP

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Doxorubicin	DMVP5YE	Acute myelogenous leukaemia	2A41	Approved	[1]
Levacecarnine hci	DMJBOCR	Cognitive impairment	6D71	Approved	[2]

Molecular Expression Atlas (MEA) of This DTP

Disease Name	ICD 11	Studied Tissue	p-value	Fold-Change	Z-score
Acute myelocytic leukaemia	2B33.1	Bone marrow	8.71E-18	-9.09E-01	-1.10E+00
Adrenocortical carcinoma	2D11.Z	Kidney	4.29E-01	-1.05E-01	-5.32E-01
Alopecia	ED70	Skin from scalp	9.49E-04	-3.94E-01	-7.64E-01
Alzheimer's disease	8A20	Entorhinal cortex	9.05E-01	-5.16E-03	-4.30E-02
Ankylosing spondylitis	FA92.0	Pheripheral blood	8.67E-01	-2.17E-02	-3.93E-02
Aortic stenosis	BB70	Calcified aortic valve	4.11E-01	1.23E-01	3.45E-01
Apnea	7A40	Hyperplastic tonsil	5.45E-01	3.92E-02	1.53E-01
Arthropathy	FA00-FA5Z	Peripheral blood	8.76E-01	2.80E-02	7.36E-02
Asthma	CA23	Nasal and bronchial airway	7.78E-01	4.47E-04	2.09E-04
Atopic dermatitis	EA80	Skin	5.80E-02	1.01E-02	1.53E-01
Autism	6A02	Whole blood	6.01E-02	-1.94E-01	-5.96E-01
Autoimmune uveitis	9A96	Peripheral monocyte	8.13E-02	4.47E-01	5.00E-01
Autosomal dominant monocytopenia	4B04	Whole blood	1.75E-02	2.54E-01	2.00E+00
Bacterial infection of gingival	1C1H	Gingival tissue	1.67E-02	1.78E-02	1.01E-01
Batten disease	5C56.1	Whole blood	8.81E-01	-2.31E-01	-8.35E-01
Behcet's disease	4A62	Peripheral blood	5.53E-01	-8.85E-02	-1.33E-01
Bipolar disorder	6A60-6A6Z	Prefrontal cortex	2.69E-01	1.24E-02	1.01E-01
Bladder cancer	2C94	Bladder tissue	1.78E-04	5.33E-01	2.64E+00
Breast cancer	2C60-2C6Z	Breast tissue	5.21E-07	-1.49E-01	-6.84E-01
Cardioembolic stroke	8B11.20	Whole blood	3.42E-03	5.64E-01	6.59E-01
Cervical cancer	2C77	Cervical tissue	4.30E-01	-7.36E-03	-4.94E-02
Childhood onset rheumatic disease	FA20.Z	Peripheral blood	5.67E-01	4.86E-02	1.90E-01
Chronic hepatitis C	1E51.1	Whole blood	4.34E-01	9.53E-02	3.56E-01
Chronic obstructive pulmonary disease	CA22	Lung tissue	5.98E-02	7.45E-02	4.24E-01
Chronic obstructive pulmonary disease	CA22	Small airway epithelium	3.71E-01	3.95E-01	2.24E-01
Chronic rhinosinusitis	CA0A	Sinus mucosa tissue	1.49E-01	-5.24E-02	-1.28E-01
Colon cancer	2B90	Colon tissue	4.34E-02	-3.08E-02	-1.82E-01
Coronary artery disease	BA80-BA8Z	Peripheral blood	1.01E-03	8.29E-01	4.65E+00
Diffuse large B-cell lymphoma	2A81	Tonsil tissue	2.63E-01	-1.69E-01	-8.10E-01
Endometriosis	GA10	Endometrium tissue	3.29E-01	3.20E-02	2.16E-01
Familial hypercholesterolemia	5C80.00	Peripheral blood	7.68E-01	-2.94E-02	-2.10E-01
Familial hypercholesterolemia	5C80.00	Whole blood	3.99E-04	6.08E-01	1.55E+00
Gastric cancer	2B72	Gastric tissue	8.83E-02	1.50E-01	1.85E+00
Glioblastopma	2A00.00	Nervous tissue	2.83E-02	-1.20E-03	-5.97E-03
Glioma	2A00.0Y-2A00.0Z	White matter tissue	1.31E-02	-4.25E-01	-1.41E+00
Head and neck cancer	2D42	Head and neck tissue	2.85E-08	-1.20E-01	-7.03E-02
HIV-associated neurocognitive impairment	8A2Y-8A2Z	White matter tissue	2.15E-01	-7.37E-04	-2.75E-03
Huntington's disease	8A01.10	Whole blood	4.76E-01	3.01E-04	1.82E-03
Idiopathic pulmonary fibrosis	CB03.4	Lung tissue	7.49E-02	-4.73E-01	-9.46E-01
Immunodeficiency	4A00-4A20	Peripheral blood	5.31E-01	-4.05E-02	-4.88E-01
Influenza	1.00E+30	Whole blood	5.93E-02	5.26E-01	2.54E+00
Interstitial cystitis	GC00.3	Bladder tissue	6.32E-01	2.52E-02	4.01E-01
Intracranial aneurysm	8B01.0	Intracranial artery	2.61E-02	2.88E-01	1.36E+00
Irritable bowel syndrome	DD91.0	Rectal colon tissue	8.78E-01	-4.63E-02	-1.57E-01
Ischemic stroke	8B11	Peripheral blood	2.95E-01	3.51E-01	8.06E-01
Juvenile idiopathic arthritis	FA24	Peripheral blood	6.87E-03	3.26E-01	4.24E-01
Lateral sclerosis	8B60.4	Cervical spinal cord	3.85E-01	3.04E-02	1.97E-01
Lateral sclerosis	8B60.4	Skin	9.68E-01	4.27E-02	3.29E-01
Liver cancer	2C12.0	Liver tissue	1.04E-06	-1.41E-01	-8.97E-01
Liver failure	DB99.7-DB99.8	Liver tissue	1.42E-01	-1.16E-01	-6.49E-01
Lung cancer	2C25	Lung tissue	6.13E-03	-1.77E-02	-4.22E-02
Lupus erythematosus	4A40	Whole blood	4.93E-02	2.16E-01	3.24E-01
Major depressive disorder	6A70-6A7Z	Whole blood	1.02E-01	3.16E-01	4.15E-01
Major depressive disorder	6A70-6A7Z	Hippocampus	7.46E-01	3.54E-02	3.40E-01
Melanoma	2C30	Skin	4.24E-01	-1.01E-01	-2.27E-01
Multiple myeloma	2A83.1	Bone marrow	3.39E-03	-2.96E-01	-1.81E+00
Multiple myeloma	2A83.1	Peripheral blood	1.11E-01	4.20E-02	2.45E-01
Multiple sclerosis	8A40	Plasmacytoid dendritic cells	5.96E-01	7.17E-02	2.89E-01
Myelodysplastic syndrome	2A36-2A3Z	Bone marrow	2.81E-01	-1.37E-01	-2.98E-01
Myelofibrosis	2A20.2	Whole blood	4.61E-02	9.50E-01	5.21E+00
Myocardial infarction	BA41-BA50	Peripheral blood	2.10E-02	5.97E-01	7.77E-01
Myopathy	8C70.6	Muscle tissue	8.66E-01	-1.14E-01	-1.03E+00
Neonatal sepsis	KA60	Whole blood	1.81E-15	4.58E-01	1.38E+00
Neuroectodermal tumour	2A00.11	Brain stem tissue	5.09E-01	-1.09E-01	-4.86E-01
Non-alcoholic fatty liver disease	DB92	Liver tissue	9.86E-02	-5.25E-02	-5.28E-01
Obesity related type 2 diabetes	5A11	Omental adipose tissue	5.55E-01	5.88E-02	4.27E-01
Olive pollen allergy	CA08.00	Peripheral blood	8.13E-01	2.48E-01	4.48E-01
Oral cancer	2B6E	Oral tissue	1.68E-01	-3.83E-02	-1.46E-01
Osteoarthritis	FA00-FA0Z	Synovial tissue	8.28E-01	-1.20E-01	-5.51E-01
Osteoporosis	FB83.1	Bone marrow	2.96E-01	1.07E-01	2.73E+00
Ovarian cancer	2C73	Ovarian tissue	1.44E-03	9.29E-02	5.94E-01
Pancreatic cancer	2C10	Pancreas	2.19E-02	-1.96E-01	-7.24E-01
Parkinson's disease	8A00.0	Substantia nigra tissue	7.90E-01	6.21E-03	4.29E-02
Pediatric respiratory syncytial virus infection	CA40.11	Peripheral blood	6.11E-04	3.47E-01	1.76E+00
Pituitary cancer	2D12	Pituitary tissue	2.73E-04	2.17E-01	1.36E+00
Pituitary gonadotrope tumour	2D12	Pituitary tissue	2.88E-02	1.84E-01	9.78E-01
Polycystic ovary syndrome	5A80.1	Vastus lateralis muscle	2.09E-01	-1.68E-02	-1.72E-01
Polycythemia vera	2A20.4	Whole blood	1.06E-06	2.01E-01	9.98E-01
Pompe disease	5C51.3	Biceps muscle	1.92E-01	-9.21E-02	-3.85E-01
Preterm birth	KA21.4Z	Myometrium	7.67E-01	7.56E-02	2.29E-01
Prostate cancer	2C82	Prostate	1.90E-02	-3.89E-01	-1.20E+00
Psoriasis	EA90	Skin	2.75E-08	-2.30E-01	-7.61E-01
Rectal cancer	2B92	Rectal colon tissue	2.88E-01	-1.62E-02	-1.40E-01
Renal cancer	2C90-2C91	Kidney	8.82E-01	-2.96E-02	-1.33E-01
Retinoblastoma	2D02.2	Uvea	2.17E-01	-1.36E-01	-1.01E+00
Rheumatoid arthritis	FA20	Synovial tissue	8.12E-04	-3.58E-01	-2.94E+00
Rhinovirus infection	CA42.1	Nasal epithelium tissue	9.39E-01	1.02E-01	8.37E-02
Schizophrenia	6A20	Prefrontal cortex	5.92E-03	6.87E-02	1.52E-01
Schizophrenia	6A20	Superior temporal cortex	5.53E-01	-2.75E-02	-2.64E-01
Scleroderma	4A42.Z	Whole blood	2.43E-02	3.56E-01	7.40E-01
Seizure	8A60-8A6Z	Whole blood	5.15E-01	-5.74E-02	-8.00E-02
Sensitive skin	EK0Z	Skin	7.50E-01	9.58E-02	4.62E-01
Sepsis with septic shock	1G41	Whole blood	4.22E-34	3.79E-01	1.14E+00
Shwachman-Diamond syndrome	3A70.0	Bone marrow	1.19E-01	4.62E-01	1.14E+00
Sickle cell disease	3A51.0-3A51.3	Peripheral blood	1.68E-01	8.63E-02	3.28E-01
Simpson golabi behmel syndrome	LD2C	Adipose tissue	8.73E-01	-7.57E-02	-3.90E-01
Sjogren's syndrome	4A43.2	Salivary gland tissue	3.10E-01	-5.36E-02	-7.34E-01
Skin cancer	2C30-2C3Z	Skin	1.26E-02	-1.55E-01	-5.47E-01
Thrombocythemia	3B63	Whole blood	1.53E-02	1.20E-01	6.53E-01
Thrombocytopenia	3B64	Whole blood	4.99E-01	3.34E-02	2.53E-01
Thyroid cancer	2D10	Thyroid	1.27E-03	3.50E-02	2.33E-01
Tibial muscular dystrophy	8C75	Muscle tissue	3.25E-01	1.49E-02	1.45E-01
Tuberous sclerosis complex	LD2D.2	Perituberal tissue	1.78E-01	1.59E-01	1.25E+00
Type 2 diabetes	5A11	Liver tissue	6.52E-01	-4.33E-02	-3.40E-01
Ureter cancer	2C92	Urothelium	7.09E-01	-5.27E-02	-2.85E-01
Uterine cancer	2C78	Endometrium tissue	1.43E-02	4.84E-02	1.60E-01
Vitiligo	ED63.0	Skin	5.31E-01	2.48E-02	5.75E-02

Drug Affinity of This DTP Assessed by Cell Line

Approved Drug(s)

Drug Name	Highest Status	Cell Line	Affinity	REF
Levacecarnine hci	Approved	Oocytes-FLIPT2	Km = 20.0 microM	[3]

The Drug Therapeutic Target (DTT) Role of This DTP

• DTP DTT Name: Solute carrier family 22 member 16 (SLC22A16) DTT Info
• DTP DTT Type: Literature-reported

References

• [1] Influence of pharmacogenetics on response and toxicity in breast cancer patients treated with doxorubicin and cyclophosphamide. Br J Cancer. 2010 Mar 16;102(6):1003-9.
• [2] The human carnitine transporter SLC22A16 mediates high affinity uptake of the anticancer polyamine analogue bleomycin-A5. J Biol Chem. 2010 Feb 26;285(9):6275-84.
• [3] Molecular identification of a novel carnitine transporter specific to human testis. Insights into the mechanism of carnitine recognition. J Biol Chem. 2002 Sep 27;277(39):36262-71.